Figure 5. HRD-HSCT group and the chemotherapy-alone group of patients with intermediate- and high-risk AML. DFS (A) and OS (B).
Figure 5

HRD-HSCT group and the chemotherapy-alone group of patients with intermediate- and high-risk AML. DFS (A) and OS (B).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal